{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+the+Bladder&page=10", "query": { "condition": "Carcinoma of the Bladder", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 1037, "total_pages": 104, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+the+Bladder&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+the+Bladder&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T22:39:42.602Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03637803", "title": "Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Oncology", "Solid Tumor", "Non Small Cell Lung Cancer", "Renal Cell Carcinoma", "Melanoma", "Bladder Cancer" ], "interventions": [ { "name": "MRx0518", "type": "DRUG" }, { "name": "Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "4D pharma plc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2019-01-10", "completion_date": "2023-05-08", "has_results": false, "last_update_posted_date": "2023-06-01", "last_synced_at": "2026-10-14T22:39:42.602Z", "location_count": 5, "location_summary": "Kansas City, Kansas • Pittsburgh, Pennsylvania • Houston, Texas + 1 more", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03637803" }, { "nct_id": "NCT01489813", "title": "Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Genistein", "type": "DRUG" }, { "name": "Sugar pill", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2017-05-19", "completion_date": "2024-08-31", "has_results": true, "last_update_posted_date": "2025-02-05", "last_synced_at": "2026-10-14T22:39:42.602Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01489813" }, { "nct_id": "NCT04155359", "title": "Clinical Evaluation of the miR Sentinel BCa™ Test to Diagnose Bladder Cancer in Hematuria Patients", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bladder Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "miR Scientific LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "45 Years to 85 Years" }, "enrollment_count": 444, "start_date": "2020-10-13", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2023-10-25", "last_synced_at": "2026-10-14T22:39:42.602Z", "location_count": 1, "location_summary": "Farmingdale, New York", "locations": [ { "city": "Farmingdale", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04155359" }, { "nct_id": "NCT00003452", "title": "Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IV Bladder Cancer" ], "interventions": [ { "name": "Antineoplaston therapy (Atengenal + Astugenal)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Burzynski Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 4, "start_date": "1996-05-06", "completion_date": "1998-05-04", "has_results": false, "last_update_posted_date": "2017-09-28", "last_synced_at": "2026-10-14T22:39:42.602Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003452" }, { "nct_id": "NCT02145871", "title": "A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "standard fluid management", "type": "OTHER" }, { "name": "fluid management guided by the EV1000", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 282, "start_date": "2014-05-21", "completion_date": "2024-03-14", "has_results": false, "last_update_posted_date": "2024-03-20", "last_synced_at": "2026-10-14T22:39:42.602Z", "location_count": 5, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 2 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02145871" }, { "nct_id": "NCT02169284", "title": "Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Carcinoma", "Recurrent Bladder Carcinoma" ], "interventions": [ { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2014-10-01", "completion_date": "2018-03-30", "has_results": true, "last_update_posted_date": "2020-07-07", "last_synced_at": "2026-10-14T22:39:42.602Z", "location_count": 6, "location_summary": "Baltimore, Maryland • Burlington, Massachusetts • Rochester, New York + 3 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Burlington", "state": "Massachusetts" }, { "city": "Rochester", "state": "New York" }, { "city": "Myrtle Beach", "state": "South Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02169284" }, { "nct_id": "NCT06111235", "title": "A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Muscle Invasive Bladder Cancer", "Urologic Cancer", "Bladder Cancer", "Urothelial Carcinoma" ], "interventions": [ { "name": "Cretostimogene Grenadenorepvec", "type": "DRUG" }, { "name": "n-dodecyl-B-D-maltoside", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "CG Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 367, "start_date": "2023-12-14", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-14T22:39:42.602Z", "location_count": 90, "location_summary": "Homewood, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 72 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06111235" }, { "nct_id": "NCT00072150", "title": "Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Bladder Cancer", "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Urethral Cancer", "Stage III Bladder Cancer", "Stage III Urethral Cancer", "Stage IV Bladder Cancer", "Stage IV Urethral Cancer", "Transitional Cell Carcinoma of the Bladder", "Ureter Cancer" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2003-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-05", "last_synced_at": "2026-10-14T22:39:42.602Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00072150" }, { "nct_id": "NCT04164082", "title": "Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Flat Urothelial Carcinoma In Situ", "Non-Muscle Invasive Bladder Urothelial Carcinoma", "Stage 0a Bladder Cancer AJCC v8", "Stage 0is Bladder Cancer AJCC v8", "Stage I Bladder Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cystoscopy", "type": "PROCEDURE" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Transurethral Resection of Bladder Tumor", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2020-03-18", "completion_date": "2026-12-09", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-14T22:39:42.602Z", "location_count": 381, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 257 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04164082" }, { "nct_id": "NCT02001623", "title": "Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovary Cancer", "Cervix Cancer", "Endometrium Cancer", "Bladder Cancer", "Prostate Cancer (CRPC)", "Esophagus Cancer", "Lung Cancer(NSCLC)", "Squamous Cell Carcinoma of the Head and Neck (SCCHN)" ], "interventions": [ { "name": "Tisotumab Vedotin (HuMax-TF-ADC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 195, "start_date": "2013-11-30", "completion_date": "2019-05-02", "has_results": true, "last_update_posted_date": "2021-12-29", "last_synced_at": "2026-10-14T22:39:42.602Z", "location_count": 8, "location_summary": "Orange, California • New Haven, Connecticut • Miami, Florida + 5 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT02001623" } ] }